GRF - Eagle Capital Growth Fund, Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
8.16
+0.07 (+0.90%)
At close: 1:03PM EDT
Stock chart is not supported by your current browser
Previous Close8.09
Open0.00
Bid7.50 x 900
Ask9.20 x 800
Day's Range8.16 - 8.18
52 Week Range6.55 - 8.45
Volume1,640
Avg. Volume2,783
Market Cap31.774M
Beta (3Y Monthly)0.65
PE Ratio (TTM)7.02
EPS (TTM)1.16
Earnings DateN/A
Forward Dividend & Yield0.53 (6.49%)
Ex-Dividend Date2018-11-21
1y Target EstN/A
Trade prices are not sourced from all markets
  • Moody's

    CPV Power Plant No.1 Bond SPV (RF) Limited -- Moody's announces completion of a periodic review of ratings of CPV Power Plant No.1 Bond SPV (RF) Limited

    Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of CPV Power Plant No.1 Bond SPV (RF) Limited and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.

  • PR Newswire

    Grifols presents additional encouraging Alzheimer's trial results at AAIC

    BARCELONA, Spain, July 16, 2019 /PRNewswire/ -- The Grifols Clinical Research team, led by Dr. Antonio Páez, today presented additional results of its AMBAR (Alzheimer Management by Albumin Replacement) clinical trial for the treatment of Alzheimer's at the Alzheimer's Association International Conference (AAIC) 2019 in Los Angeles (USA).

  • PR Newswire

    Grifols Announces FDA Approval of Xembify®, 20% Subcutaneous Immunoglobulin for Primary Immunodeficiencies

    BARCELONA, Spain, July 4, 2019 /PRNewswire/ -- Grifols (GRF.MC) (GRF.P.MC) (GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify®, its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (FDA).  Xembify® is used to treat primary immunodeficiencies.

  • PR Newswire

    Grifols Selected to Build Its First Intravenous Solutions Manufacturing Line in Africa

    BARCELONA, Spain, July 3, 2019 /PRNewswire/ -- Grifols (GRF.MC) (GRF.P.MC) (GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced it has been selected by Soludia Maghreb, a provider of hemodialysis solutions headquartered in Morocco, as the main supplier for a new manufacturing plant in northern Africa. Grifols will develop, build and automate the main process equipment for the IV solutions line.  Grifols Engineering, which provides technology and consultancy services to the pharmaceutical and biotech sectors, will design a state-of-the-art manufacturing line that will produce intravenous solutions bags. This is the first industrial project for Grifols on the African continent.

  • PR Newswire

    Grifols to launch plasma-protein-based bleeding-control solutions

    BARCELONA, Spain, June 19, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that the VISTASEAL™ fibrin sealant will be the first product it will introduce with Ethicon Inc. as part of a broad global relationship to provide plasma-protein-based solutions to manage surgical bleeding. Grifols developed VISTASEAL™, which combines two plasma proteins, fibrinogen and thrombin, and is administered with Ethicon's airless spray device technology.

  • Morningstar

    How International Is Your Foreign-Stock Fund?

    This article originally appeared in Morningstar Direct Cloud and Morningstar Office Cloud. For investors trying to assess the diversification benefits of international-equity funds, it's important to have a clear understanding of how much overseas economic exposure a portfolio truly has. In March, we published an article examining how some major U.S. stock exchange-traded funds are more exposed overseas than the traditional ways of assessing country exposure would suggest.

  • PR Newswire

    Grifols Announces PharmacyKeeper Bidirectional Integration with Epic

    BARCELONA, Spain, April 30, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, announced today that its PharmacyKeeper Verification IV Workflow Management system now supports bidirectional integration with Epic.

  • PR Newswire

    Grifols Announces the Opening of its new Plasma Donor Center in Hinesville, Georgia

    Investing $1.6 million into local community; set to employ over 40 people from the local area HINESVILLE, Ga. , April 29, 2019 /PRNewswire/ -- Grifols is pleased to announce the opening of a new Biotest ...

  • PR Newswire

    Grifols US donor centers exceed 250,000 pounds of food collected

    - About 20% of children in the U.S. are frequently hungry while nearly 50 million Americans do not get enough to eat. RALEIGH, N.C., April 18, 2019 /PRNewswire/ -- Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its U.S. network of over 220 donor centers collaborated with local food banks and pantries to collect more than 250,000 pounds of groceries to help address food insecurity in local communities. According to Feeding America, a leading national hunger non-profit, the 253,000 pounds of food collected translates into 211,000i meals to help support the over 50,000 familiesii that cannot put sufficient food on the table.

  • Grifols donations of blood clotting factor helping people with hemophilia globally
    PR Newswire

    Grifols donations of blood clotting factor helping people with hemophilia globally

    - The company has donated more than 100 million international units (IUs) of blood clotting factor medicines globally during multi-year commitment to the WFH in developing regions. - Grifols creates Grifols Humanitarian Awards in Hemophilia to strengthen the global fight against the disease. BARCELONA, Spain, April 15, 2019 /PRNewswire/ -- Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its long-term global initiative to providing treatment to people with hemophilia in developing regions has surpassed 100 million international units (IUs) in donated blood clotting factor, a protein in blood that controls bleeding.

  • PR Newswire

    Grifols 2018 Annual Report on Form 20-F Filed With the SEC on April 5, 2019

    BARCELONA, Spain , April 5, 2019 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) announced that it has filed its 2018 Annual Report on Form 20-F with the United ...

  • Grifols Receives FDA Approval for Procleix Babesia Assay for Donor Screening on Procleix Panther System
    PR Newswire

    Grifols Receives FDA Approval for Procleix Babesia Assay for Donor Screening on Procleix Panther System

    BARCELONA, Spain, Feb. 7, 2019 /PRNewswire/ -- Grifols, a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, announced today that the U.S. Food and Drug Administration (FDA) approved the Procleix Babesia assay, a qualitative assay for the detection of the ribosomal RNA from 4  Babesia species (B. microti, B. duncani, B. divergens, B. venatorum) in individual samples or up to 16 pooled lysed specimens from human donors, including donors of whole blood and blood components for transfusion.

  • Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe
    PR Newswire

    Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe

    - Grifols gains exclusive rights to fostamatinib in all potential indications in Europe and Turkey - Rigel to receive an upfront payment of $30 million , with the potential for $297.5 million in total ...

  • Grifols receives FDA approval of Erytra Eflexis®, the latest advancement in scalable blood typing solutions
    PR Newswire

    Grifols receives FDA approval of Erytra Eflexis®, the latest advancement in scalable blood typing solutions

    - Erytra Eflexis is a fully automated, benchtop analyzer that performs pretransfusion compatibility testing - This system incorporates two laboratory configurations in a single instrument, providing laboratory ...

  • Grifols demonstrates a significant reduction (61%) in the progression of moderate Alzheimer's disease using its AMBAR treatment protocol
    PR Newswire

    Grifols demonstrates a significant reduction (61%) in the progression of moderate Alzheimer's disease using its AMBAR treatment protocol

    - AMBAR, an innovative treatment approach for Alzheimer's disease (AD) using plasma science has demonstrated, with statistical significance, the ability to slow down the progression of the disease in moderate AD patients. BARCELONA, Spain, Oct. 27, 2018 /PRNewswire/ -- Presenting the study results, Antonio Páez, M.D., Grifols Medical Director and Head of the AMBAR Clinical Program confirmed that the analysis of AMBAR data in moderate patients has shown positive, highly relevant results in a cohort of patients suffering from moderate Alzheimer's disease.